Bio-Rad LaboratoriesBIO -3.25%72 PB Ratio is 1.11 as of Jul. 08, 2026, which is 34% below its 10-year median of 1.68. GuruFocus rates BIO with a GF Score™ of 72/100 and a GF Value™ of $317.96 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks better than 74.84% on this metric.
The historical rank and industry rank for Bio-Rad Laboratories's PB Ratio or its related term are showing as below:
BIO'
s PB Ratio Range Over the Past 10 Years
Min: 0.86 Med: 1.68 Max: 2.81
Current: 1.11
During the past 13 years, Bio-Rad Laboratories's highest PB Ratio was 2.81. The lowest was 0.86. And the median was 1.68.
BIO's PB Ratio is ranked better than 74.84% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.06
vs BIO: 1.11
During the past 12 months, Bio-Rad Laboratories's average Book Value Per Share Growth Rate was 5.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -5.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -8.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 15.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Bio-Rad Laboratories was 50.20% per year. The lowest was -20.00% per year. And the median was 14.60% per year.
Back to Basics: PB Ratio
Bio-Rad Laboratories (NYSE:BIO) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Bio-Rad Laboratories PB Ratio Related Terms
Bio-Rad Laboratories PB Ratio Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bio-Rad Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bio-Rad Laboratories (BIO) has a PB Ratio of 1.11 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bio-Rad Laboratories and its competitors. This is 34% below median its historical median of 1.68. Over the past decade, Bio-Rad Laboratories' PB Ratio has ranged from 0.86 to 2.81. According to the industry distribution chart, Bio-Rad Laboratories ranks #198 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 25.2%.
Is Bio-Rad Laboratories' PB Ratio too high?
Bio-Rad Laboratories' current PB Ratio of 1.11 is 34% below median its 10-year median of 1.68. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 2.81. The Medical Devices & Instruments industry median PB Ratio is 2.06. Bio-Rad Laboratories' value of 1.11 is 46.1% below this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #198 out of 787 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' PB Ratio compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #198 out of 787 companies for PB Ratio. This puts Bio-Rad Laboratories in the upper half of its industry. The industry median PB Ratio is 2.06. Bio-Rad Laboratories' value of 1.11 is 46.1% below this benchmark. Historically, Bio-Rad Laboratories' own PB Ratio has ranged from 0.86 to 2.81 over the past decade. While the company's 10-year median is 1.68 vs. the industry median of 2.06, Bio-Rad Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.06, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current PB Ratio of 1.11 is 46.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current PB Ratio is 1.11, which is 34% below median its own 10-year median of 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (BIO) is currently considered Modestly Undervalued. The stock's GF Value™ is $317.96, compared to a current price of $282.98 — trading 11% below its estimated fair value. The current PB Ratio is 1.11, which is 34% below median its 10-year median of 1.68 and 46.1% below the Medical Devices & Instruments industry median of 2.06. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bio-Rad Laboratories (BIO), the current PB Ratio is 1.11 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued.
The current stock price of $282.98 is trading 11% below its estimated GF Value™ of $317.96.
GuruFocus considers Bio-Rad Laboratories to be Modestly Undervalued.
Key valuation signals for BIO:
PB Ratio: 1.11 (34% below median its 10-year median of 1.68)
GF Value™: $317.96 vs. price of $282.98 (11% below fair value)
Industry Position: 46.1% below the Medical Devices & Instruments median (#198 of 787)
No single metric tells the full story. See the BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score
Get the complete analysis for BIO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIO has been successfully added to your 
